Exact Mass: 600.3364

Exact Mass Matches: 600.3364

Found 225 metabolites which its exact mass value is equals to given mass value 600.3364, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

5-Oxoavermectin 2a aglycone

5-Oxoavermectin 2a aglycone

C34H48O9 (600.3298)


   

LysoPI(0:0/18:0)

[(2R)-3-hydroxy-2-(octadecanoyloxy)propoxy]({[(1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxy})phosphinic acid

C27H53O12P (600.3274)


LysoPI(0:0/18:0) is a lysophosphatidylinositol. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic. However, it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Lysophosphatidylinositols can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. LysoPI(0:0/18:0), in particular, consists of one chain of stearic acid at the C-2 position.

   

LysoPI(18:0/0:0)

[(2R)-2-hydroxy-3-(octadecanoyloxy)propoxy]({[(1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxy})phosphinic acid

C27H53O12P (600.3274)


LysoPI(18:0/0:0) is a lysophosphatidylinositol. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic. However, it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Lysophosphatidylinositols can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. LysoPI(18:0/0:0), in particular, consists of one chain of stearic acid at the C-1 position.

   

4-[3-[3-[Bis[4-(2-methylpropyl)phenyl]methylamino]benzoyl]indol-1-yl]butanoic acid

4-{3-[3-({bis[4-(2-methylpropyl)phenyl]methyl}amino)benzoyl]-1H-indol-1-yl}butanoic acid

C40H44N2O3 (600.3352)


   

PA(8:0/20:3(5Z,8Z,11Z)-O(14R,15S))

[(2R)-3-(octanoyloxy)-2-{[(5Z,8Z,11Z)-13-(3-pentyloxiran-2-yl)trideca-5,8,11-trienoyl]oxy}propoxy]phosphonic acid

C31H53O9P (600.3427)


PA(8:0/20:3(5Z,8Z,11Z)-O(14R,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:3(5Z,8Z,11Z)-O(14R,15S)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 14,15-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(5Z,8Z,11Z)-O(14R,15S)/8:0)

[(2R)-2-(octanoyloxy)-3-{[(5Z,8Z,11Z)-13-(3-pentyloxiran-2-yl)trideca-5,8,11-trienoyl]oxy}propoxy]phosphonic acid

C31H53O9P (600.3427)


PA(20:3(5Z,8Z,11Z)-O(14R,15S)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,8Z,11Z)-O(14R,15S)/8:0), in particular, consists of one chain of one 14,15-epoxyeicosatrienoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(8:0/20:3(5Z,8Z,14Z)-O(11S,12R))

[(2R)-2-{[(5Z,8Z)-10-{3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl}deca-5,8-dienoyl]oxy}-3-(octanoyloxy)propoxy]phosphonic acid

C31H53O9P (600.3427)


PA(8:0/20:3(5Z,8Z,14Z)-O(11S,12R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:3(5Z,8Z,14Z)-O(11S,12R)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 11,12-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(5Z,8Z,14Z)-O(11S,12R)/8:0)

[(2R)-3-{[(5Z,8Z)-10-{3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl}deca-5,8-dienoyl]oxy}-2-(octanoyloxy)propoxy]phosphonic acid

C31H53O9P (600.3427)


PA(20:3(5Z,8Z,14Z)-O(11S,12R)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,8Z,14Z)-O(11S,12R)/8:0), in particular, consists of one chain of one 11,12-epoxyeicosatrienoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(8:0/20:3(5Z,11Z,14Z)-O(8,9))

[(2R)-3-(octanoyloxy)-2-{[(5Z)-7-{3-[(2Z,5Z)-undeca-2,5-dien-1-yl]oxiran-2-yl}hept-5-enoyl]oxy}propoxy]phosphonic acid

C31H53O9P (600.3427)


PA(8:0/20:3(5Z,11Z,14Z)-O(8,9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:3(5Z,11Z,14Z)-O(8,9)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 8,9--epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(5Z,11Z,14Z)-O(8,9)/8:0)

[(2R)-2-(octanoyloxy)-3-{[(5Z)-7-{3-[(2Z,5Z)-undeca-2,5-dien-1-yl]oxiran-2-yl}hept-5-enoyl]oxy}propoxy]phosphonic acid

C31H53O9P (600.3427)


PA(20:3(5Z,11Z,14Z)-O(8,9)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,11Z,14Z)-O(8,9)/8:0), in particular, consists of one chain of one 8,9--epoxyeicosatrienoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(8:0/20:3(8Z,11Z,14Z)-O(5,6))

[(2R)-3-(octanoyloxy)-2-[(4-{3-[(2Z,5Z,8Z)-tetradeca-2,5,8-trien-1-yl]oxiran-2-yl}butanoyl)oxy]propoxy]phosphonic acid

C31H53O9P (600.3427)


PA(8:0/20:3(8Z,11Z,14Z)-O(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:3(8Z,11Z,14Z)-O(5,6)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 5,6-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(8Z,11Z,14Z)-O(5,6)/8:0)

[(2R)-2-(octanoyloxy)-3-[(4-{3-[(2Z,5Z,8Z)-tetradeca-2,5,8-trien-1-yl]oxiran-2-yl}butanoyl)oxy]propoxy]phosphonic acid

C31H53O9P (600.3427)


PA(20:3(8Z,11Z,14Z)-O(5,6)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-O(5,6)/8:0), in particular, consists of one chain of one 5,6-epoxyeicosatrienoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(20))

[(2R)-2-{[(5Z,8Z,11Z,14Z)-20-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-3-(octanoyloxy)propoxy]phosphonic acid

C31H53O9P (600.3427)


PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(20)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(20)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 20-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/8:0)

[(2R)-3-{[(5Z,8Z,11Z,14Z)-20-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-2-(octanoyloxy)propoxy]phosphonic acid

C31H53O9P (600.3427)


PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/8:0), in particular, consists of one chain of one 20-Hydroxyeicosatetraenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(8:0/20:4(6E,8Z,11Z,14Z)-OH(5S))

[(2R)-2-{[(5R,6E,8Z,11Z,14Z)-5-hydroxyicosa-6,8,11,14-tetraenoyl]oxy}-3-(octanoyloxy)propoxy]phosphonic acid

C31H53O9P (600.3427)


PA(8:0/20:4(6E,8Z,11Z,14Z)-OH(5S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:4(6E,8Z,11Z,14Z)-OH(5S)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 5-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/8:0)

[(2R)-3-{[(5S,6E,8Z,11Z,14Z)-5-hydroxyicosa-6,8,11,14-tetraenoyl]oxy}-2-(octanoyloxy)propoxy]phosphonic acid

C31H53O9P (600.3427)


PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/8:0), in particular, consists of one chain of one 5-Hydroxyeicosatetraenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))

[(2R)-2-{[(5Z,8Z,11Z,14Z,19S)-19-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-3-(octanoyloxy)propoxy]phosphonic acid

C31H53O9P (600.3427)


PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 19-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/8:0)

[(2R)-3-{[(5Z,8Z,11Z,14Z,19R)-19-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-2-(octanoyloxy)propoxy]phosphonic acid

C31H53O9P (600.3427)


PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/8:0), in particular, consists of one chain of one 19-Hydroxyeicosatetraenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))

[(2R)-2-{[(5Z,8Z,11Z,14Z,18R)-18-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-3-(octanoyloxy)propoxy]phosphonic acid

C31H53O9P (600.3427)


PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 18-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/8:0)

[(2R)-3-{[(5Z,8Z,11Z,14Z,18S)-18-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-2-(octanoyloxy)propoxy]phosphonic acid

C31H53O9P (600.3427)


PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/8:0), in particular, consists of one chain of one 18-Hydroxyeicosatetraenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(17))

[(2R)-2-{[(5Z,8Z,11Z,14Z)-17-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-3-(octanoyloxy)propoxy]phosphonic acid

C31H53O9P (600.3427)


PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(17)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 17-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/8:0)

[(2R)-3-{[(5Z,8Z,11Z,14Z)-17-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-2-(octanoyloxy)propoxy]phosphonic acid

C31H53O9P (600.3427)


PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/8:0), in particular, consists of one chain of one 17-Hydroxyeicosatetraenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))

[(2R)-2-{[(5Z,8Z,11Z,14Z,16R)-16-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-3-(octanoyloxy)propoxy]phosphonic acid

C31H53O9P (600.3427)


PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 16-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/8:0)

[(2R)-3-{[(5Z,8Z,11Z,14Z,16S)-16-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-2-(octanoyloxy)propoxy]phosphonic acid

C31H53O9P (600.3427)


PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/8:0), in particular, consists of one chain of one 16-Hydroxyeicosatetraenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(8:0/20:4(5Z,8Z,11Z,13E)-OH(15S))

[(2R)-2-{[(5Z,8Z,11Z,13E,15S)-15-hydroxyicosa-5,8,11,13-tetraenoyl]oxy}-3-(octanoyloxy)propoxy]phosphonic acid

C31H53O9P (600.3427)


PA(8:0/20:4(5Z,8Z,11Z,13E)-OH(15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:4(5Z,8Z,11Z,13E)-OH(15S)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 15-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/8:0)

[(2R)-3-{[(5Z,8Z,11Z,13E,15R)-15-hydroxyicosa-5,8,11,13-tetraenoyl]oxy}-2-(octanoyloxy)propoxy]phosphonic acid

C31H53O9P (600.3427)


PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/8:0), in particular, consists of one chain of one 15-Hydroxyeicosatetraenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(8:0/20:4(5Z,8Z,10E,14Z)-OH(12S))

[(2R)-2-{[(5Z,8Z,10E,12S,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoyl]oxy}-3-(octanoyloxy)propoxy]phosphonic acid

C31H53O9P (600.3427)


PA(8:0/20:4(5Z,8Z,10E,14Z)-OH(12S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:4(5Z,8Z,10E,14Z)-OH(12S)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 12-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/8:0)

[(2R)-3-{[(5Z,8Z,10E,12R,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoyl]oxy}-2-(octanoyloxy)propoxy]phosphonic acid

C31H53O9P (600.3427)


PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/8:0), in particular, consists of one chain of one 12-Hydroxyeicosatetraenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(8:0/20:4(5E,8Z,12Z,14Z)-OH(11R))

[(2R)-2-{[(5E,8Z,11R,12Z,14Z)-11-hydroxyicosa-5,8,12,14-tetraenoyl]oxy}-3-(octanoyloxy)propoxy]phosphonic acid

C31H53O9P (600.3427)


PA(8:0/20:4(5E,8Z,12Z,14Z)-OH(11R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:4(5E,8Z,12Z,14Z)-OH(11R)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 11-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/8:0)

[(2R)-3-{[(5E,8Z,11S,12Z,14Z)-11-hydroxyicosa-5,8,12,14-tetraenoyl]oxy}-2-(octanoyloxy)propoxy]phosphonic acid

C31H53O9P (600.3427)


PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/8:0), in particular, consists of one chain of one 11-Hydroxyeicosatetraenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(8:0/20:4(5Z,7E,11Z,14Z)-OH(9))

[(2R)-2-{[(5E,7Z,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoyl]oxy}-3-(octanoyloxy)propoxy]phosphonic acid

C31H53O9P (600.3427)


PA(8:0/20:4(5Z,7E,11Z,14Z)-OH(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:4(5Z,7E,11Z,14Z)-OH(9)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 9-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,7E,11Z,14Z)-OH(9)/8:0)

[(2R)-3-{[(5E,7Z,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoyl]oxy}-2-(octanoyloxy)propoxy]phosphonic acid

C31H53O9P (600.3427)


PA(20:4(5Z,7E,11Z,14Z)-OH(9)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,7E,11Z,14Z)-OH(9)/8:0), in particular, consists of one chain of one 9-Hydroxyeicosatetraenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

Desoxygambogenin

Desoxygambogenin

C38H48O6 (600.3451)


   
   

3-O-Geranylforbesione

3-O-Geranylforbesione

C38H48O6 (600.3451)


   
   

dichapetalin B

dichapetalin B

C38H48O6 (600.3451)


   

(+)-garcinialiptone

(+)-garcinialiptone

C38H48O6 (600.3451)


   

Phebaloparvilactone

Phebaloparvilactone

C34H48O9 (600.3298)


   

(2R,5S,6S,7R,8S,9S,10S,18R,19R)-18,19-diacetoxy-18,19-epoxy-2-[(2Z,4E)-decadienoyloxy-6,7-dihydroxy]cleroda-3,12(E),14-triene|argutin C

(2R,5S,6S,7R,8S,9S,10S,18R,19R)-18,19-diacetoxy-18,19-epoxy-2-[(2Z,4E)-decadienoyloxy-6,7-dihydroxy]cleroda-3,12(E),14-triene|argutin C

C34H48O9 (600.3298)


   

bufotalin 3-hemisuberate|Korksaeure-mono-<3>bufotalylester|Korksaeure-mono-[3]bufotalylester

bufotalin 3-hemisuberate|Korksaeure-mono-<3>bufotalylester|Korksaeure-mono-[3]bufotalylester

C34H48O9 (600.3298)


   

oblongifolin G

oblongifolin G

C38H48O6 (600.3451)


   

12xi-acetoxy-11beta-hydroxypetuniasterone D 7-acetate

12xi-acetoxy-11beta-hydroxypetuniasterone D 7-acetate

C34H48O9 (600.3298)


   

garcicowin D

garcicowin D

C38H48O6 (600.3451)


   

milbemycin alpha22

milbemycin alpha22

C34H48O9 (600.3298)


   

petuniasterone J

petuniasterone J

C34H48O9 (600.3298)


   

(2R,5S,6S,7R,8S,9S,10S,18R,19R)-18,19-diacetoxy-18,19-epoxy-2,7-dihydroxy-6-[(2Z,4E)-decadienoyloxy]cleroda-3,12(E),14-triene|argutin D

(2R,5S,6S,7R,8S,9S,10S,18R,19R)-18,19-diacetoxy-18,19-epoxy-2,7-dihydroxy-6-[(2Z,4E)-decadienoyloxy]cleroda-3,12(E),14-triene|argutin D

C34H48O9 (600.3298)


   

oxy-guttiferone M

oxy-guttiferone M

C38H48O6 (600.3451)


   

oxy-guttiferone K

oxy-guttiferone K

C38H48O6 (600.3451)


   

polypodin B-22-O-benzoate|polypodine B-22-O-benzoate

polypodin B-22-O-benzoate|polypodine B-22-O-benzoate

C34H48O9 (600.3298)


   

symphonone H

symphonone H

C38H48O6 (600.3451)


   

(20R,22S)-1-oxo-witha-2,5,24-trienolide-20-beta-ol 20-beta-D-glucopyranoside|glucosomniferanolide

(20R,22S)-1-oxo-witha-2,5,24-trienolide-20-beta-ol 20-beta-D-glucopyranoside|glucosomniferanolide

C34H48O9 (600.3298)


   

nujiangefolin A

nujiangefolin A

C38H48O6 (600.3451)


   

nujiangefolin B

nujiangefolin B

C38H48O6 (600.3451)


   

11,25-dideacetyl trichostemonate

11,25-dideacetyl trichostemonate

C34H48O9 (600.3298)


   

oxy-thorelione A

oxy-thorelione A

C38H48O6 (600.3451)


   

rel-(1R,3S,5R,7S,8R)-1-(3,4-dihydroxybenzoyl)-6,6-dimethyl-5-(3-methylbut-2-en-1-yl)-3-[5-methyl-2-(1-methylethenyl)hex-4-en-1-yl]-8-(2-methylprop-1-en-1-yl)tricyclo[3,3,1,13,7]decane-2,4,9-trione

rel-(1R,3S,5R,7S,8R)-1-(3,4-dihydroxybenzoyl)-6,6-dimethyl-5-(3-methylbut-2-en-1-yl)-3-[5-methyl-2-(1-methylethenyl)hex-4-en-1-yl]-8-(2-methylprop-1-en-1-yl)tricyclo[3,3,1,13,7]decane-2,4,9-trione

C38H48O6 (600.3451)


   

symphonone A

symphonone A

C38H48O6 (600.3451)


   

biyouxanthone A

biyouxanthone A

C38H48O6 (600.3451)


   

16alpha,25-Diacetoxy-2beta,20-dihydroxy-10alpha-cucurbita-5,23t-dien-3,11,22-trion|16alpha,25-diacetoxy-2beta,20-dihydroxy-10alpha-cucurbita-5,23t-diene-3,11,22-trione|Fabacein

16alpha,25-Diacetoxy-2beta,20-dihydroxy-10alpha-cucurbita-5,23t-dien-3,11,22-trion|16alpha,25-diacetoxy-2beta,20-dihydroxy-10alpha-cucurbita-5,23t-diene-3,11,22-trione|Fabacein

C34H48O9 (600.3298)


   

klysimplexin sulfoxide B

klysimplexin sulfoxide B

C31H52O9S (600.3332)


   
   

oxy-guttiferone K2

oxy-guttiferone K2

C38H48O6 (600.3451)


   

2,16-Di-O-acetylcucurbitacin D|2,16-Di-O-acetylcucurbitacin R|2beta,16alpha-Diacetoxy-20,25-dihydroxy-10alpha-cucurbita-5,23t-dien-3,11,22-trion|2beta,16alpha-diacetoxy-20,25-dihydroxy-10alpha-cucurbita-5,23t-diene-3,11,22-trione

2,16-Di-O-acetylcucurbitacin D|2,16-Di-O-acetylcucurbitacin R|2beta,16alpha-Diacetoxy-20,25-dihydroxy-10alpha-cucurbita-5,23t-dien-3,11,22-trion|2beta,16alpha-diacetoxy-20,25-dihydroxy-10alpha-cucurbita-5,23t-diene-3,11,22-trione

C34H48O9 (600.3298)


   

symphonone I

symphonone I

C38H48O6 (600.3451)


   

daturametelin A

daturametelin A

C34H48O9 (600.3298)


   
   

Gly Leu Arg Asn Gln

Gly Leu Arg Asn Gln

C24H44N10O8 (600.3343)


   

Phosphatidylinositol lyso 18:0

Phosphatidylinositol lyso 18:0

C27H53O12P (600.3274)


   

[2-hydroxy-3-[hydroxy-[2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropyl] octadecanoate

[2-hydroxy-3-[hydroxy-[2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropyl] octadecanoate

C27H53O12P (600.3274)


   

Lys Lys Tyr Tyr

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2,6-diaminohexanamido]hexanamido]-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanoic acid

C30H44N6O7 (600.3271)


   

Lys Tyr Lys Tyr

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-(4-hydroxyphenyl)propanamido]hexanamido]-3-(4-hydroxyphenyl)propanoic acid

C30H44N6O7 (600.3271)


   

Lys Tyr Tyr Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]hexanoic acid

C30H44N6O7 (600.3271)


   

Tyr Lys Lys Tyr

(2S)-2-[(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]hexanamido]hexanamido]-3-(4-hydroxyphenyl)propanoic acid

C30H44N6O7 (600.3271)


   

Tyr Lys Tyr Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]hexanamido]-3-(4-hydroxyphenyl)propanamido]hexanoic acid

C30H44N6O7 (600.3271)


   

Tyr Tyr Lys Lys

(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]hexanamido]hexanoic acid

C30H44N6O7 (600.3271)


   

PI(18:0/0:0)

1-octadecanoyl-sn-glycero-3-phospho-(1-myo-inositol)

C27H53O12P (600.3274)


   

LPI 18:0

1-octadecanoyl-sn-glycero-3-phospho-(1-myo-inositol)

C27H53O12P (600.3274)


   

Glc-GP 18:0

1-octadecanoyl-sn-glycero-3-phospho-(1-beta-D-glucose)

C27H53O12P (600.3274)


   

valnemulin Hydrochloride

valnemulin Hydrochloride

C31H53ClN2O5S (600.3364)


   

4-[3-[3-[Bis[4-(2-methylpropyl)phenyl]methylamino]benzoyl]indol-1-yl]butanoic acid

4-[3-[3-[Bis[4-(2-methylpropyl)phenyl]methylamino]benzoyl]indol-1-yl]butanoic acid

C40H44N2O3 (600.3352)


D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D065088 - Steroid Synthesis Inhibitors D004791 - Enzyme Inhibitors > D065088 - Steroid Synthesis Inhibitors > D058891 - 5-alpha Reductase Inhibitors

   

1-stearoyl-sn-glycero-3-phospho-1D-myo-inositol

1-stearoyl-sn-glycero-3-phospho-1D-myo-inositol

C27H53O12P (600.3274)


A 1-acyl-sn-glycero-3-phospho-1D-myo-inositol in which the 1-acyl group is specified as stearoyl.

   

2-Stearoylglycerophosphoinositol

2-Stearoylglycerophosphoinositol

C27H53O12P (600.3274)


   

PA(8:0/20:4(6E,8Z,11Z,14Z)-OH(5S))

PA(8:0/20:4(6E,8Z,11Z,14Z)-OH(5S))

C31H53O9P (600.3427)


   

PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/8:0)

PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/8:0)

C31H53O9P (600.3427)


   

PA(8:0/20:4(5Z,7E,11Z,14Z)-OH(9))

PA(8:0/20:4(5Z,7E,11Z,14Z)-OH(9))

C31H53O9P (600.3427)


   

PA(20:4(5Z,7E,11Z,14Z)-OH(9)/8:0)

PA(20:4(5Z,7E,11Z,14Z)-OH(9)/8:0)

C31H53O9P (600.3427)


   

PA(8:0/20:3(5Z,8Z,11Z)-O(14R,15S))

PA(8:0/20:3(5Z,8Z,11Z)-O(14R,15S))

C31H53O9P (600.3427)


   

PA(20:3(5Z,8Z,11Z)-O(14R,15S)/8:0)

PA(20:3(5Z,8Z,11Z)-O(14R,15S)/8:0)

C31H53O9P (600.3427)


   

PA(8:0/20:3(5Z,8Z,14Z)-O(11S,12R))

PA(8:0/20:3(5Z,8Z,14Z)-O(11S,12R))

C31H53O9P (600.3427)


   

PA(20:3(5Z,8Z,14Z)-O(11S,12R)/8:0)

PA(20:3(5Z,8Z,14Z)-O(11S,12R)/8:0)

C31H53O9P (600.3427)


   

PA(8:0/20:3(5Z,11Z,14Z)-O(8,9))

PA(8:0/20:3(5Z,11Z,14Z)-O(8,9))

C31H53O9P (600.3427)


   

PA(20:3(5Z,11Z,14Z)-O(8,9)/8:0)

PA(20:3(5Z,11Z,14Z)-O(8,9)/8:0)

C31H53O9P (600.3427)


   

PA(8:0/20:3(8Z,11Z,14Z)-O(5,6))

PA(8:0/20:3(8Z,11Z,14Z)-O(5,6))

C31H53O9P (600.3427)


   

PA(20:3(8Z,11Z,14Z)-O(5,6)/8:0)

PA(20:3(8Z,11Z,14Z)-O(5,6)/8:0)

C31H53O9P (600.3427)


   

PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(20))

PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(20))

C31H53O9P (600.3427)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/8:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/8:0)

C31H53O9P (600.3427)


   

PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))

PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))

C31H53O9P (600.3427)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/8:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/8:0)

C31H53O9P (600.3427)


   

PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))

PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))

C31H53O9P (600.3427)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/8:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/8:0)

C31H53O9P (600.3427)


   

PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(17))

PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(17))

C31H53O9P (600.3427)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/8:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/8:0)

C31H53O9P (600.3427)


   

PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))

PA(8:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))

C31H53O9P (600.3427)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/8:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/8:0)

C31H53O9P (600.3427)


   

PA(8:0/20:4(5Z,8Z,11Z,13E)-OH(15S))

PA(8:0/20:4(5Z,8Z,11Z,13E)-OH(15S))

C31H53O9P (600.3427)


   

PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/8:0)

PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/8:0)

C31H53O9P (600.3427)


   

PA(8:0/20:4(5Z,8Z,10E,14Z)-OH(12S))

PA(8:0/20:4(5Z,8Z,10E,14Z)-OH(12S))

C31H53O9P (600.3427)


   

PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/8:0)

PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/8:0)

C31H53O9P (600.3427)


   

PA(8:0/20:4(5E,8Z,12Z,14Z)-OH(11R))

PA(8:0/20:4(5E,8Z,12Z,14Z)-OH(11R))

C31H53O9P (600.3427)


   

PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/8:0)

PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/8:0)

C31H53O9P (600.3427)


   

2-[[(2R)-3-acetyloxy-2-[(6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(2R)-3-acetyloxy-2-[(6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C30H51NO9P+ (600.3301)


   

2-[[(2R)-2-acetyloxy-3-[(6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(2R)-2-acetyloxy-3-[(6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C30H51NO9P+ (600.3301)


   

2-[[(2R)-3-acetyloxy-2-[(5Z,8Z,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(2R)-3-acetyloxy-2-[(5Z,8Z,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C30H51NO9P+ (600.3301)


   

2-[[(2R)-2-acetyloxy-3-[(5Z,8Z,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(2R)-2-acetyloxy-3-[(5Z,8Z,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C30H51NO9P+ (600.3301)


   

2-[[(2R)-3-acetyloxy-2-[(5Z,8Z,11Z,14Z,16E,18R)-18-hydroxyicosa-5,8,11,14,16-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(2R)-3-acetyloxy-2-[(5Z,8Z,11Z,14Z,16E,18R)-18-hydroxyicosa-5,8,11,14,16-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C30H51NO9P+ (600.3301)


   

2-[[(2R)-2-acetyloxy-3-[(5Z,8Z,11Z,14Z,16E,18S)-18-hydroxyicosa-5,8,11,14,16-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(2R)-2-acetyloxy-3-[(5Z,8Z,11Z,14Z,16E,18S)-18-hydroxyicosa-5,8,11,14,16-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C30H51NO9P+ (600.3301)


   

2-[[(2R)-3-acetyloxy-2-[(5Z,8Z,11Z,13E,17Z)-16-hydroxyicosa-5,8,11,13,17-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(2R)-3-acetyloxy-2-[(5Z,8Z,11Z,13E,17Z)-16-hydroxyicosa-5,8,11,13,17-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C30H51NO9P+ (600.3301)


   

2-[[(2R)-2-acetyloxy-3-[(5Z,8Z,11Z,13E,17Z)-16-hydroxyicosa-5,8,11,13,17-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(2R)-2-acetyloxy-3-[(5Z,8Z,11Z,13E,17Z)-16-hydroxyicosa-5,8,11,13,17-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C30H51NO9P+ (600.3301)


   

2-[[(2R)-3-acetyloxy-2-[(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(2R)-3-acetyloxy-2-[(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C30H51NO9P+ (600.3301)


   

2-[[(2R)-2-acetyloxy-3-[(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(2R)-2-acetyloxy-3-[(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C30H51NO9P+ (600.3301)


   

2-[[(2R)-3-acetyloxy-2-[(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(2R)-3-acetyloxy-2-[(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C30H51NO9P+ (600.3301)


   

2-[[(2R)-2-acetyloxy-3-[(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(2R)-2-acetyloxy-3-[(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C30H51NO9P+ (600.3301)


   

casearupestrin B

casearupestrin B

C34H48O9 (600.3298)


   

Casearupestrin A

Casearupestrin A

C34H48O9 (600.3298)


   

Argutin C

Argutin C

C34H48O9 (600.3298)


A natural product found in Casearia arguta.

   

Argutin D

Argutin D

C34H48O9 (600.3298)


A natural product found in Casearia arguta.

   

(2R)-2-hydroxy-3-[(hydroxy{[(1S,2R,3S,4S,5S,6S)-2,3,4,5,6-pentahydroxycyclohexyl]oxy}phosphoryl)oxy]propyl stearate

(2R)-2-hydroxy-3-[(hydroxy{[(1S,2R,3S,4S,5S,6S)-2,3,4,5,6-pentahydroxycyclohexyl]oxy}phosphoryl)oxy]propyl stearate

C27H53O12P (600.3274)


   

5-Oxoavermectin2a aglycone

5-Oxoavermectin 2a aglycone

C34H48O9 (600.3298)


   

[2-Hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] octadecanoate

[2-Hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] octadecanoate

C27H53O12P (600.3274)


   

Casearupestrin B, (rel)-

Casearupestrin B, (rel)-

C34H48O9 (600.3298)


A natural product found in Casearia rupestris.

   

Casearupestrin A, (rel)-

Casearupestrin A, (rel)-

C34H48O9 (600.3298)


A natural product found in Casearia rupestris.

   

1-octadecanoyl-sn-glycero-3-phospho-(1-myo-inositol)

1-octadecanoyl-sn-glycero-3-phospho-(1-myo-inositol)

C27H53O12P (600.3274)


   
   

PA P-16:1/12:3;O2

PA P-16:1/12:3;O2

C31H53O9P (600.3427)


   

PA P-20:1/8:3;O2

PA P-20:1/8:3;O2

C31H53O9P (600.3427)


   

PA 16:1/12:3;O

PA 16:1/12:3;O

C31H53O9P (600.3427)


   

PA 20:1/8:3;O

PA 20:1/8:3;O

C31H53O9P (600.3427)


   

PA 20:3/8:1;O

PA 20:3/8:1;O

C31H53O9P (600.3427)


   

PA 22:2/6:2;O

PA 22:2/6:2;O

C31H53O9P (600.3427)


   
   
   
   

6-O-(1-O-Stearoyl-sn-glycero-3-phosphono)-1D-myo-inositol

6-O-(1-O-Stearoyl-sn-glycero-3-phosphono)-1D-myo-inositol

C27H53O12P (600.3274)


   
   
   
   
   
   

ST 28:5;O3;GlcA

ST 28:5;O3;GlcA

C34H48O9 (600.3298)


   

ST 28:6;O4;Hex

ST 28:6;O4;Hex

C34H48O9 (600.3298)


   

(1s,3r,5r,6as,7s,8s,9r,10r,10as)-1,3-bis(acetyloxy)-9,10-dihydroxy-7,8-dimethyl-7-[(2e)-3-methylpenta-2,4-dien-1-yl]-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-5-yl (2z,4e)-deca-2,4-dienoate

(1s,3r,5r,6as,7s,8s,9r,10r,10as)-1,3-bis(acetyloxy)-9,10-dihydroxy-7,8-dimethyl-7-[(2e)-3-methylpenta-2,4-dien-1-yl]-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-5-yl (2z,4e)-deca-2,4-dienoate

C34H48O9 (600.3298)


   

1-(3,7-dimethylocta-2,6-dien-1-yl)-3,8-dihydroxy-1,5,5-tris(3-methylbut-2-en-1-yl)xanthene-2,6,9-trione

1-(3,7-dimethylocta-2,6-dien-1-yl)-3,8-dihydroxy-1,5,5-tris(3-methylbut-2-en-1-yl)xanthene-2,6,9-trione

C38H48O6 (600.3451)


   

(1s,3r,5r,6as,7s,8s,9r,10s,10as)-1,3-bis(acetyloxy)-5,9-dihydroxy-7,8-dimethyl-7-[(2e)-3-methylpenta-2,4-dien-1-yl]-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-10-yl (2e,4e)-deca-2,4-dienoate

(1s,3r,5r,6as,7s,8s,9r,10s,10as)-1,3-bis(acetyloxy)-5,9-dihydroxy-7,8-dimethyl-7-[(2e)-3-methylpenta-2,4-dien-1-yl]-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-10-yl (2e,4e)-deca-2,4-dienoate

C34H48O9 (600.3298)


   

(6s,9s,12s,15s,20as)-9-benzyl-15-[(2s)-butan-2-yl]-1,4,7,10,13-pentahydroxy-12-(hydroxymethyl)-6-isopropyl-3h,6h,9h,12h,15h,18h,19h,20h,20ah-pyrrolo[1,2-a]1,4,7,10,13,16-hexaazacyclooctadecan-16-one

(6s,9s,12s,15s,20as)-9-benzyl-15-[(2s)-butan-2-yl]-1,4,7,10,13-pentahydroxy-12-(hydroxymethyl)-6-isopropyl-3h,6h,9h,12h,15h,18h,19h,20h,20ah-pyrrolo[1,2-a]1,4,7,10,13,16-hexaazacyclooctadecan-16-one

C30H44N6O7 (600.3271)


   

7-(3,4-dihydroxybenzoyl)-4,4,10,10-tetramethyl-3,9-bis(3-methylbut-2-en-1-yl)-11-(3-methylbuta-1,3-dien-1-yl)-5-oxatricyclo[7.3.1.0¹,⁶]tridec-6-ene-8,13-dione

7-(3,4-dihydroxybenzoyl)-4,4,10,10-tetramethyl-3,9-bis(3-methylbut-2-en-1-yl)-11-(3-methylbuta-1,3-dien-1-yl)-5-oxatricyclo[7.3.1.0¹,⁶]tridec-6-ene-8,13-dione

C38H48O6 (600.3451)


   

4-(acetyloxy)-10-hydroxy-9a,11a-dimethyl-7-oxo-1-(1-{1,5,6,6-tetramethyl-2,7,8-trioxabicyclo[3.2.1]octan-3-yl}ethyl)-1h,2h,3h,3ah,3bh,4h,5h,9bh,10h,11h-cyclopenta[a]phenanthren-11-yl acetate

4-(acetyloxy)-10-hydroxy-9a,11a-dimethyl-7-oxo-1-(1-{1,5,6,6-tetramethyl-2,7,8-trioxabicyclo[3.2.1]octan-3-yl}ethyl)-1h,2h,3h,3ah,3bh,4h,5h,9bh,10h,11h-cyclopenta[a]phenanthren-11-yl acetate

C34H48O9 (600.3298)


   

(1'r,2r,4's,5s,6r,8'r,10'e,13'r,14'e,16'e,20'r,21'r,24's)-21',24'-dihydroxy-5,6,11',13'-tetramethyl-2'-oxo-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-22'-ylmethyl propanoate

(1'r,2r,4's,5s,6r,8'r,10'e,13'r,14'e,16'e,20'r,21'r,24's)-21',24'-dihydroxy-5,6,11',13'-tetramethyl-2'-oxo-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-22'-ylmethyl propanoate

C34H48O9 (600.3298)


   

3,4-dimethoxy-2-(methoxymethyl)-6-[(1,3,4,5-tetramethoxypentan-2-yl)oxy]-5-[(3,4,5-trimethoxy-6-methyloxan-2-yl)oxy]oxane

3,4-dimethoxy-2-(methoxymethyl)-6-[(1,3,4,5-tetramethoxypentan-2-yl)oxy]-5-[(3,4,5-trimethoxy-6-methyloxan-2-yl)oxy]oxane

C27H52O14 (600.3357)


   

(2r,13r,15s)-13-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6,8-dihydroxy-17,17-dimethyl-5,15-bis(3-methylbut-2-en-1-yl)-3,16-dioxapentacyclo[11.4.1.0²,¹¹.0²,¹⁵.0⁴,⁹]octadeca-4,6,8,11-tetraene-10,14-dione

(2r,13r,15s)-13-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6,8-dihydroxy-17,17-dimethyl-5,15-bis(3-methylbut-2-en-1-yl)-3,16-dioxapentacyclo[11.4.1.0²,¹¹.0²,¹⁵.0⁴,⁹]octadeca-4,6,8,11-tetraene-10,14-dione

C38H48O6 (600.3451)


   

(1r,3s,5r,7s,8r)-1-(3,4-dihydroxybenzoyl)-6,6-dimethyl-3-[5-methyl-2-(prop-1-en-2-yl)hex-5-en-1-yl]-5-(3-methylbut-2-en-1-yl)-8-(2-methylprop-1-en-1-yl)adamantane-2,4,9-trione

(1r,3s,5r,7s,8r)-1-(3,4-dihydroxybenzoyl)-6,6-dimethyl-3-[5-methyl-2-(prop-1-en-2-yl)hex-5-en-1-yl]-5-(3-methylbut-2-en-1-yl)-8-(2-methylprop-1-en-1-yl)adamantane-2,4,9-trione

C38H48O6 (600.3451)


   

(1s,2s,13s,15r)-7-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6,8-dihydroxy-17,17-dimethyl-5,15-bis(3-methylbut-2-en-1-yl)-3,16-dioxapentacyclo[11.4.1.0²,¹¹.0²,¹⁵.0⁴,⁹]octadeca-4,6,8,11-tetraene-10,14-dione

(1s,2s,13s,15r)-7-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6,8-dihydroxy-17,17-dimethyl-5,15-bis(3-methylbut-2-en-1-yl)-3,16-dioxapentacyclo[11.4.1.0²,¹¹.0²,¹⁵.0⁴,⁹]octadeca-4,6,8,11-tetraene-10,14-dione

C38H48O6 (600.3451)


   

(6r)-6-[(1s)-1-[(1r,3as,3bs,9ar,9bs,11as)-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethyl]-4-methyl-3-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-5,6-dihydropyran-2-one

(6r)-6-[(1s)-1-[(1r,3as,3bs,9ar,9bs,11as)-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethyl]-4-methyl-3-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-5,6-dihydropyran-2-one

C34H48O9 (600.3298)


   

13-(3,7-dimethylocta-2,6-dien-1-yl)-6,7-dihydroxy-16,16-dimethyl-1,15-bis(3-methylbut-2-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione

13-(3,7-dimethylocta-2,6-dien-1-yl)-6,7-dihydroxy-16,16-dimethyl-1,15-bis(3-methylbut-2-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione

C38H48O6 (600.3451)


   

15-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6,7-dihydroxy-16,16-dimethyl-1,13-bis(3-methylbut-2-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione

15-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6,7-dihydroxy-16,16-dimethyl-1,13-bis(3-methylbut-2-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione

C38H48O6 (600.3451)


   

(1r,13r,15s)-15-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6,7-dihydroxy-16,16-dimethyl-1,13-bis(3-methylbut-2-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione

(1r,13r,15s)-15-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6,7-dihydroxy-16,16-dimethyl-1,13-bis(3-methylbut-2-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione

C38H48O6 (600.3451)


   

(1s,13s,15s)-5,6-dihydroxy-16,16-dimethyl-13-[(2s)-5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl]-1,15-bis(3-methylbut-2-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione

(1s,13s,15s)-5,6-dihydroxy-16,16-dimethyl-13-[(2s)-5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl]-1,15-bis(3-methylbut-2-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione

C38H48O6 (600.3451)


   

6-(1-{9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}ethyl)-4-methyl-3-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-5,6-dihydropyran-2-one

6-(1-{9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}ethyl)-4-methyl-3-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-5,6-dihydropyran-2-one

C34H48O9 (600.3298)


   

6,12,13-trihydroxy-18,18-dimethyl-3,17,19-tris(3-methylbut-2-en-1-yl)-4-methylidene-15-oxapentacyclo[15.3.1.0¹,⁶.0⁷,¹⁶.0⁹,¹⁴]henicosa-7(16),9,11,13-tetraene-8,21-dione

6,12,13-trihydroxy-18,18-dimethyl-3,17,19-tris(3-methylbut-2-en-1-yl)-4-methylidene-15-oxapentacyclo[15.3.1.0¹,⁶.0⁷,¹⁶.0⁹,¹⁴]henicosa-7(16),9,11,13-tetraene-8,21-dione

C38H48O6 (600.3451)


   

17-(acetyloxy)-2,16-dimethyl-5-oxo-15-(1-{1,5,6,6-tetramethyl-2,7,8-trioxabicyclo[3.2.1]octan-3-yl}ethyl)-7-oxapentacyclo[9.7.0.0²,⁸.0⁶,⁸.0¹²,¹⁶]octadec-3-en-10-yl acetate

17-(acetyloxy)-2,16-dimethyl-5-oxo-15-(1-{1,5,6,6-tetramethyl-2,7,8-trioxabicyclo[3.2.1]octan-3-yl}ethyl)-7-oxapentacyclo[9.7.0.0²,⁸.0⁶,⁸.0¹²,¹⁶]octadec-3-en-10-yl acetate

C34H48O9 (600.3298)


   

(2r,3r)-2-[(1s,3as,5as,7r,8s,9ar,9br,11ar)-3a,5a,7,8-tetrahydroxy-9a,11a-dimethyl-5-oxo-1h,2h,3h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-2,6-dihydroxy-6-methylheptan-3-yl benzoate

(2r,3r)-2-[(1s,3as,5as,7r,8s,9ar,9br,11ar)-3a,5a,7,8-tetrahydroxy-9a,11a-dimethyl-5-oxo-1h,2h,3h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-2,6-dihydroxy-6-methylheptan-3-yl benzoate

C34H48O9 (600.3298)


   

(1s,13s,15s)-13-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6,7-dihydroxy-16,16-dimethyl-1,15-bis(3-methylbut-2-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione

(1s,13s,15s)-13-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6,7-dihydroxy-16,16-dimethyl-1,15-bis(3-methylbut-2-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione

C38H48O6 (600.3451)


   

3-{2'-hydroxy-3,4,5',9',9',14',18'-heptamethyl-5,12'-dioxo-21'-oxaspiro[oxolane-2,20'-pentacyclo[12.8.0.0¹,¹⁷.0⁴,¹³.0⁵,¹⁰]docosan]-4'(13')-en-8'-yloxy}-3-oxopropanoic acid

3-{2'-hydroxy-3,4,5',9',9',14',18'-heptamethyl-5,12'-dioxo-21'-oxaspiro[oxolane-2,20'-pentacyclo[12.8.0.0¹,¹⁷.0⁴,¹³.0⁵,¹⁰]docosan]-4'(13')-en-8'-yloxy}-3-oxopropanoic acid

C34H48O9 (600.3298)


   

(1s,3r,5s,7r,8s)-1-(3,4-dihydroxybenzoyl)-6,6-dimethyl-3-[(2r)-5-methyl-2-(prop-1-en-2-yl)hex-5-en-1-yl]-5-(3-methylbut-2-en-1-yl)-8-(2-methylprop-1-en-1-yl)adamantane-2,4,9-trione

(1s,3r,5s,7r,8s)-1-(3,4-dihydroxybenzoyl)-6,6-dimethyl-3-[(2r)-5-methyl-2-(prop-1-en-2-yl)hex-5-en-1-yl]-5-(3-methylbut-2-en-1-yl)-8-(2-methylprop-1-en-1-yl)adamantane-2,4,9-trione

C38H48O6 (600.3451)


   

(1r,3s,5r,7s,8r)-1-(3,4-dihydroxybenzoyl)-6,6-dimethyl-3-[(2r)-5-methyl-2-(prop-1-en-2-yl)hex-5-en-1-yl]-5-(3-methylbut-2-en-1-yl)-8-(2-methylprop-1-en-1-yl)adamantane-2,4,9-trione

(1r,3s,5r,7s,8r)-1-(3,4-dihydroxybenzoyl)-6,6-dimethyl-3-[(2r)-5-methyl-2-(prop-1-en-2-yl)hex-5-en-1-yl]-5-(3-methylbut-2-en-1-yl)-8-(2-methylprop-1-en-1-yl)adamantane-2,4,9-trione

C38H48O6 (600.3451)


   

(1s,2r,6r,8r,10r,11s,12s,15r,16r,17s)-17-(acetyloxy)-2,16-dimethyl-5-oxo-15-[(1s)-1-[(1s,3r,5r)-1,5,6,6-tetramethyl-2,7,8-trioxabicyclo[3.2.1]octan-3-yl]ethyl]-7-oxapentacyclo[9.7.0.0²,⁸.0⁶,⁸.0¹²,¹⁶]octadec-3-en-10-yl acetate

(1s,2r,6r,8r,10r,11s,12s,15r,16r,17s)-17-(acetyloxy)-2,16-dimethyl-5-oxo-15-[(1s)-1-[(1s,3r,5r)-1,5,6,6-tetramethyl-2,7,8-trioxabicyclo[3.2.1]octan-3-yl]ethyl]-7-oxapentacyclo[9.7.0.0²,⁸.0⁶,⁸.0¹²,¹⁶]octadec-3-en-10-yl acetate

C34H48O9 (600.3298)


   

(1s,3s,6s,17s,19s)-6,12,13-trihydroxy-18,18-dimethyl-3,17,19-tris(3-methylbut-2-en-1-yl)-4-methylidene-15-oxapentacyclo[15.3.1.0¹,⁶.0⁷,¹⁶.0⁹,¹⁴]henicosa-7(16),9,11,13-tetraene-8,21-dione

(1s,3s,6s,17s,19s)-6,12,13-trihydroxy-18,18-dimethyl-3,17,19-tris(3-methylbut-2-en-1-yl)-4-methylidene-15-oxapentacyclo[15.3.1.0¹,⁶.0⁷,¹⁶.0⁹,¹⁴]henicosa-7(16),9,11,13-tetraene-8,21-dione

C38H48O6 (600.3451)


   

(1r,13r,15s)-13-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6,7-dihydroxy-16,16-dimethyl-1,15-bis(3-methylbut-2-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione

(1r,13r,15s)-13-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6,7-dihydroxy-16,16-dimethyl-1,15-bis(3-methylbut-2-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione

C38H48O6 (600.3451)


   

1,3-bis(acetyloxy)-5,9-dihydroxy-7,8-dimethyl-7-(3-methylidenepent-4-en-1-yl)-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-10-yl deca-2,4-dienoate

1,3-bis(acetyloxy)-5,9-dihydroxy-7,8-dimethyl-7-(3-methylidenepent-4-en-1-yl)-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-10-yl deca-2,4-dienoate

C34H48O9 (600.3298)


   

(1r,13r,15r)-15-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6,7-dihydroxy-16,16-dimethyl-1,13-bis(3-methylbut-2-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione

(1r,13r,15r)-15-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6,7-dihydroxy-16,16-dimethyl-1,13-bis(3-methylbut-2-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione

C38H48O6 (600.3451)


   

(1r,3r,5r,6as,7s,8s,9r,10r,10as)-1,3-bis(acetyloxy)-5,9-dihydroxy-7,8-dimethyl-7-(3-methylidenepent-4-en-1-yl)-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-10-yl (2e,4e)-deca-2,4-dienoate

(1r,3r,5r,6as,7s,8s,9r,10r,10as)-1,3-bis(acetyloxy)-5,9-dihydroxy-7,8-dimethyl-7-(3-methylidenepent-4-en-1-yl)-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-10-yl (2e,4e)-deca-2,4-dienoate

C34H48O9 (600.3298)


   

(1r,2s,6s,8r,10s,11r,12s,13r,16r,17r,19s,20r)-17-(acetyloxy)-8-(furan-3-yl)-12-hydroxy-4-methoxy-1,9,11,16-tetramethyl-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icosan-19-yl (2e)-2-methylbut-2-enoate

(1r,2s,6s,8r,10s,11r,12s,13r,16r,17r,19s,20r)-17-(acetyloxy)-8-(furan-3-yl)-12-hydroxy-4-methoxy-1,9,11,16-tetramethyl-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icosan-19-yl (2e)-2-methylbut-2-enoate

C34H48O9 (600.3298)


   

6,7-dihydroxy-14-methyl-1,13,15-tris(3-methylbut-2-en-1-yl)-14-(4-methylpent-3-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione

6,7-dihydroxy-14-methyl-1,13,15-tris(3-methylbut-2-en-1-yl)-14-(4-methylpent-3-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione

C38H48O6 (600.3451)


   

(1r,2s,4r,5r,8r,9s,11s)-9-formyl-2-({[(2r,3s,4s,5r,6r)-3-hydroxy-5-methoxy-6-methyl-4-{[(2e,4z)-2-methylhexa-2,4-dienoyl]oxy}oxan-2-yl]oxy}methyl)-13-isopropyl-5-methyltetracyclo[7.4.0.0²,¹¹.0⁴,⁸]tridec-12-ene-1-carboxylic acid

(1r,2s,4r,5r,8r,9s,11s)-9-formyl-2-({[(2r,3s,4s,5r,6r)-3-hydroxy-5-methoxy-6-methyl-4-{[(2e,4z)-2-methylhexa-2,4-dienoyl]oxy}oxan-2-yl]oxy}methyl)-13-isopropyl-5-methyltetracyclo[7.4.0.0²,¹¹.0⁴,⁸]tridec-12-ene-1-carboxylic acid

C34H48O9 (600.3298)


   

1,3-bis(acetyloxy)-5,10-dihydroxy-7,8-dimethyl-7-(3-methylidenepent-4-en-1-yl)-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-9-yl deca-2,4-dienoate

1,3-bis(acetyloxy)-5,10-dihydroxy-7,8-dimethyl-7-(3-methylidenepent-4-en-1-yl)-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-9-yl deca-2,4-dienoate

C34H48O9 (600.3298)


   

3-[(1'r,2s,2'r,3s,4s,5's,8'r,10'r,14'r,17'r,18'r)-2'-hydroxy-3,4,5',9',9',14',18'-heptamethyl-5,12'-dioxo-21'-oxaspiro[oxolane-2,20'-pentacyclo[12.8.0.0¹,¹⁷.0⁴,¹³.0⁵,¹⁰]docosan]-4'(13')-en-8'-yloxy]-3-oxopropanoic acid

3-[(1'r,2s,2'r,3s,4s,5's,8'r,10'r,14'r,17'r,18'r)-2'-hydroxy-3,4,5',9',9',14',18'-heptamethyl-5,12'-dioxo-21'-oxaspiro[oxolane-2,20'-pentacyclo[12.8.0.0¹,¹⁷.0⁴,¹³.0⁵,¹⁰]docosan]-4'(13')-en-8'-yloxy]-3-oxopropanoic acid

C34H48O9 (600.3298)


   

5-(acetyloxy)-14-(butanoyloxy)-6-hydroxy-3-isopropyl-10-methanesulfinyl-6,10,14-trimethyl-15-oxatricyclo[6.6.1.0²,⁷]pentadecan-4-yl butanoate

5-(acetyloxy)-14-(butanoyloxy)-6-hydroxy-3-isopropyl-10-methanesulfinyl-6,10,14-trimethyl-15-oxatricyclo[6.6.1.0²,⁷]pentadecan-4-yl butanoate

C31H52O9S (600.3332)


   

1,3-bis(acetyloxy)-5,9-dihydroxy-7,8-dimethyl-7-(3-methylpenta-2,4-dien-1-yl)-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-10-yl deca-2,4-dienoate

1,3-bis(acetyloxy)-5,9-dihydroxy-7,8-dimethyl-7-(3-methylpenta-2,4-dien-1-yl)-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-10-yl deca-2,4-dienoate

C34H48O9 (600.3298)


   

(1r)-1-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-3,8-dihydroxy-1,5,5-tris(3-methylbut-2-en-1-yl)xanthene-2,6,9-trione

(1r)-1-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-3,8-dihydroxy-1,5,5-tris(3-methylbut-2-en-1-yl)xanthene-2,6,9-trione

C38H48O6 (600.3451)


   

5,6-dihydroxy-16,16-dimethyl-13-[5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl]-1,15-bis(3-methylbut-2-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione

5,6-dihydroxy-16,16-dimethyl-13-[5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl]-1,15-bis(3-methylbut-2-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione

C38H48O6 (600.3451)


   

(1s,3r,5s,7r,8s)-1-(3,4-dihydroxybenzoyl)-6,6-dimethyl-3-[5-methyl-2-(prop-1-en-2-yl)hex-5-en-1-yl]-5-(3-methylbut-2-en-1-yl)-8-(2-methylprop-1-en-1-yl)adamantane-2,4,9-trione

(1s,3r,5s,7r,8s)-1-(3,4-dihydroxybenzoyl)-6,6-dimethyl-3-[5-methyl-2-(prop-1-en-2-yl)hex-5-en-1-yl]-5-(3-methylbut-2-en-1-yl)-8-(2-methylprop-1-en-1-yl)adamantane-2,4,9-trione

C38H48O6 (600.3451)


   

(1s,3r,5r,6as,7s,8s,9r,10s,10as)-1,3-bis(acetyloxy)-9,10-dihydroxy-7,8-dimethyl-7-[(2e)-3-methylpenta-2,4-dien-1-yl]-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-5-yl (4e)-deca-2,4-dienoate

(1s,3r,5r,6as,7s,8s,9r,10s,10as)-1,3-bis(acetyloxy)-9,10-dihydroxy-7,8-dimethyl-7-[(2e)-3-methylpenta-2,4-dien-1-yl]-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-5-yl (4e)-deca-2,4-dienoate

C34H48O9 (600.3298)


   

(1s,3s,9r,11r)-7-(3,4-dihydroxybenzoyl)-4,4,10,10-tetramethyl-3,9-bis(3-methylbut-2-en-1-yl)-11-[(1e)-3-methylbuta-1,3-dien-1-yl]-5-oxatricyclo[7.3.1.0¹,⁶]tridec-6-ene-8,13-dione

(1s,3s,9r,11r)-7-(3,4-dihydroxybenzoyl)-4,4,10,10-tetramethyl-3,9-bis(3-methylbut-2-en-1-yl)-11-[(1e)-3-methylbuta-1,3-dien-1-yl]-5-oxatricyclo[7.3.1.0¹,⁶]tridec-6-ene-8,13-dione

C38H48O6 (600.3451)


   

1-(3,4-dihydroxybenzoyl)-6,6-dimethyl-3-[5-methyl-2-(prop-1-en-2-yl)hex-5-en-1-yl]-5-(3-methylbut-2-en-1-yl)-8-(2-methylprop-1-en-1-yl)adamantane-2,4,9-trione

1-(3,4-dihydroxybenzoyl)-6,6-dimethyl-3-[5-methyl-2-(prop-1-en-2-yl)hex-5-en-1-yl]-5-(3-methylbut-2-en-1-yl)-8-(2-methylprop-1-en-1-yl)adamantane-2,4,9-trione

C38H48O6 (600.3451)


   

9'-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-8',10'-dihydroxy-3',3',4-trimethyl-11'-(3-methylbut-2-en-1-yl)-4',6'a-dihydro-3'ah-spiro[cyclohexane-1,1'-furo[3,4-e]xanthen]-3-ene-5,7'-dione

9'-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-8',10'-dihydroxy-3',3',4-trimethyl-11'-(3-methylbut-2-en-1-yl)-4',6'a-dihydro-3'ah-spiro[cyclohexane-1,1'-furo[3,4-e]xanthen]-3-ene-5,7'-dione

C38H48O6 (600.3451)


   

6,7-dihydroxy-16-methyl-1,13,15-tris(3-methylbut-2-en-1-yl)-16-(4-methylpent-3-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione

6,7-dihydroxy-16-methyl-1,13,15-tris(3-methylbut-2-en-1-yl)-16-(4-methylpent-3-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione

C38H48O6 (600.3451)


   

(1s,3r,5r,6as,7s,8s,9r,10s,10as)-1,3-bis(acetyloxy)-9,10-dihydroxy-7,8-dimethyl-7-[(2e)-3-methylpenta-2,4-dien-1-yl]-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-5-yl (2z,4e)-deca-2,4-dienoate

(1s,3r,5r,6as,7s,8s,9r,10s,10as)-1,3-bis(acetyloxy)-9,10-dihydroxy-7,8-dimethyl-7-[(2e)-3-methylpenta-2,4-dien-1-yl]-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-5-yl (2z,4e)-deca-2,4-dienoate

C34H48O9 (600.3298)


   

(1s,3r,5r,6as,7s,8s,9r,10r,10as)-1,3-bis(acetyloxy)-5,9-dihydroxy-7,8-dimethyl-7-[(2e)-3-methylpenta-2,4-dien-1-yl]-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-10-yl (2z,4e)-deca-2,4-dienoate

(1s,3r,5r,6as,7s,8s,9r,10r,10as)-1,3-bis(acetyloxy)-5,9-dihydroxy-7,8-dimethyl-7-[(2e)-3-methylpenta-2,4-dien-1-yl]-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-10-yl (2z,4e)-deca-2,4-dienoate

C34H48O9 (600.3298)


   

(1r,2r,3r,4s,5r,6s,7s,8r,10r,14r)-5-(acetyloxy)-14-(butanoyloxy)-6-hydroxy-3-isopropyl-10-[(r)-methanesulfinyl]-6,10,14-trimethyl-15-oxatricyclo[6.6.1.0²,⁷]pentadecan-4-yl butanoate

(1r,2r,3r,4s,5r,6s,7s,8r,10r,14r)-5-(acetyloxy)-14-(butanoyloxy)-6-hydroxy-3-isopropyl-10-[(r)-methanesulfinyl]-6,10,14-trimethyl-15-oxatricyclo[6.6.1.0²,⁷]pentadecan-4-yl butanoate

C31H52O9S (600.3332)


   

6-[2-(acetyloxy)-8-hydroxy-3a,6,6,9b,11a-pentamethyl-7,10-dioxo-1h,2h,3h,3bh,4h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-1-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl acetate

6-[2-(acetyloxy)-8-hydroxy-3a,6,6,9b,11a-pentamethyl-7,10-dioxo-1h,2h,3h,3bh,4h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-1-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl acetate

C34H48O9 (600.3298)


   

21',24'-dihydroxy-5,6,11',13'-tetramethyl-2'-oxo-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-22'-ylmethyl propanoate

21',24'-dihydroxy-5,6,11',13'-tetramethyl-2'-oxo-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-22'-ylmethyl propanoate

C34H48O9 (600.3298)


   

garcicowin c

garcicowin c

C38H48O6 (600.3451)


   

(1r,3as,3bs,4r,9ar,9bs,10r,11s,11ar)-4-(acetyloxy)-10-hydroxy-9a,11a-dimethyl-7-oxo-1-[(1s)-1-[(1s,3r,5r)-1,5,6,6-tetramethyl-2,7,8-trioxabicyclo[3.2.1]octan-3-yl]ethyl]-1h,2h,3h,3ah,3bh,4h,5h,9bh,10h,11h-cyclopenta[a]phenanthren-11-yl acetate

(1r,3as,3bs,4r,9ar,9bs,10r,11s,11ar)-4-(acetyloxy)-10-hydroxy-9a,11a-dimethyl-7-oxo-1-[(1s)-1-[(1s,3r,5r)-1,5,6,6-tetramethyl-2,7,8-trioxabicyclo[3.2.1]octan-3-yl]ethyl]-1h,2h,3h,3ah,3bh,4h,5h,9bh,10h,11h-cyclopenta[a]phenanthren-11-yl acetate

C34H48O9 (600.3298)


   

(3e,6r)-6-[(1r,2r,3as,3bs,8s,9ar,9br,11ar)-2-(acetyloxy)-8-hydroxy-3a,6,6,9b,11a-pentamethyl-7,10-dioxo-1h,2h,3h,3bh,4h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-1-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl acetate

(3e,6r)-6-[(1r,2r,3as,3bs,8s,9ar,9br,11ar)-2-(acetyloxy)-8-hydroxy-3a,6,6,9b,11a-pentamethyl-7,10-dioxo-1h,2h,3h,3bh,4h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-1-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl acetate

C34H48O9 (600.3298)


   

(1r,3r,5r,6as,7s,8s,9r,10r,10as)-1,3-bis(acetyloxy)-5,10-dihydroxy-7,8-dimethyl-7-(3-methylidenepent-4-en-1-yl)-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-9-yl (2e,4e)-deca-2,4-dienoate

(1r,3r,5r,6as,7s,8s,9r,10r,10as)-1,3-bis(acetyloxy)-5,10-dihydroxy-7,8-dimethyl-7-(3-methylidenepent-4-en-1-yl)-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-9-yl (2e,4e)-deca-2,4-dienoate

C34H48O9 (600.3298)


   

(1s,2s,13s,15r)-6-{[(2e)-3,7-dimethylocta-2,6-dien-1-yl]oxy}-8-hydroxy-17,17-dimethyl-5,15-bis(3-methylbut-2-en-1-yl)-3,16-dioxapentacyclo[11.4.1.0²,¹¹.0²,¹⁵.0⁴,⁹]octadeca-4,6,8,11-tetraene-10,14-dione

(1s,2s,13s,15r)-6-{[(2e)-3,7-dimethylocta-2,6-dien-1-yl]oxy}-8-hydroxy-17,17-dimethyl-5,15-bis(3-methylbut-2-en-1-yl)-3,16-dioxapentacyclo[11.4.1.0²,¹¹.0²,¹⁵.0⁴,⁹]octadeca-4,6,8,11-tetraene-10,14-dione

C38H48O6 (600.3451)


   

15-(3,7-dimethylocta-2,6-dien-1-yl)-6,7-dihydroxy-16,16-dimethyl-1,13-bis(3-methylbut-2-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione

15-(3,7-dimethylocta-2,6-dien-1-yl)-6,7-dihydroxy-16,16-dimethyl-1,13-bis(3-methylbut-2-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione

C38H48O6 (600.3451)


   

7-(3,7-dimethylocta-2,6-dien-1-yl)-6,8-dihydroxy-17,17-dimethyl-5,15-bis(3-methylbut-2-en-1-yl)-3,16-dioxapentacyclo[11.4.1.0²,¹¹.0²,¹⁵.0⁴,⁹]octadeca-4,6,8,11-tetraene-10,14-dione

7-(3,7-dimethylocta-2,6-dien-1-yl)-6,8-dihydroxy-17,17-dimethyl-5,15-bis(3-methylbut-2-en-1-yl)-3,16-dioxapentacyclo[11.4.1.0²,¹¹.0²,¹⁵.0⁴,⁹]octadeca-4,6,8,11-tetraene-10,14-dione

C38H48O6 (600.3451)


   

[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18s)-11-ethyl-9-hydroxy-4,6,8,16,18-pentamethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methyl 2-aminobenzoate

[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18s)-11-ethyl-9-hydroxy-4,6,8,16,18-pentamethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methyl 2-aminobenzoate

C33H48N2O8 (600.341)


   

(4r,5r,8r,9s)-9-formyl-2-({[(2r,3s,4s,5r,6r)-3-hydroxy-5-methoxy-6-methyl-4-{[(2z,4e)-2-methylhexa-2,4-dienoyl]oxy}oxan-2-yl]oxy}methyl)-13-isopropyl-5-methyltetracyclo[7.4.0.0²,¹¹.0⁴,⁸]tridec-12-ene-1-carboxylic acid

(4r,5r,8r,9s)-9-formyl-2-({[(2r,3s,4s,5r,6r)-3-hydroxy-5-methoxy-6-methyl-4-{[(2z,4e)-2-methylhexa-2,4-dienoyl]oxy}oxan-2-yl]oxy}methyl)-13-isopropyl-5-methyltetracyclo[7.4.0.0²,¹¹.0⁴,⁸]tridec-12-ene-1-carboxylic acid

C34H48O9 (600.3298)


   

6-[(3,7-dimethylocta-2,6-dien-1-yl)oxy]-8-hydroxy-17,17-dimethyl-5,15-bis(3-methylbut-2-en-1-yl)-3,16-dioxapentacyclo[11.4.1.0²,¹¹.0²,¹⁵.0⁴,⁹]octadeca-4,6,8,11-tetraene-10,14-dione

6-[(3,7-dimethylocta-2,6-dien-1-yl)oxy]-8-hydroxy-17,17-dimethyl-5,15-bis(3-methylbut-2-en-1-yl)-3,16-dioxapentacyclo[11.4.1.0²,¹¹.0²,¹⁵.0⁴,⁹]octadeca-4,6,8,11-tetraene-10,14-dione

C38H48O6 (600.3451)


   

(1r,13r,15r,16s)-6,7-dihydroxy-16-methyl-1,13,15-tris(3-methylbut-2-en-1-yl)-16-(4-methylpent-3-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione

(1r,13r,15r,16s)-6,7-dihydroxy-16-methyl-1,13,15-tris(3-methylbut-2-en-1-yl)-16-(4-methylpent-3-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione

C38H48O6 (600.3451)


   

(3s,4r,5s)-4-hydroxy-3-[(1s,2r,3r,5r,6r,9s,14s,15r,18s,19s)-3-hydroxy-2,6,14-trimethyl-9-phenyl-8-oxahexacyclo[16.3.1.0¹,¹⁸.0²,¹⁵.0⁵,¹⁴.0⁶,¹¹]docosa-11,16-dien-19-yl]-5-[(1e)-3-hydroxy-2-methylprop-1-en-1-yl]oxolan-2-one

(3s,4r,5s)-4-hydroxy-3-[(1s,2r,3r,5r,6r,9s,14s,15r,18s,19s)-3-hydroxy-2,6,14-trimethyl-9-phenyl-8-oxahexacyclo[16.3.1.0¹,¹⁸.0²,¹⁵.0⁵,¹⁴.0⁶,¹¹]docosa-11,16-dien-19-yl]-5-[(1e)-3-hydroxy-2-methylprop-1-en-1-yl]oxolan-2-one

C38H48O6 (600.3451)


   

9-formyl-2-[({3-hydroxy-5-methoxy-6-methyl-4-[(2-methylhexa-2,4-dienoyl)oxy]oxan-2-yl}oxy)methyl]-13-isopropyl-5-methyltetracyclo[7.4.0.0²,¹¹.0⁴,⁸]tridec-12-ene-1-carboxylic acid

9-formyl-2-[({3-hydroxy-5-methoxy-6-methyl-4-[(2-methylhexa-2,4-dienoyl)oxy]oxan-2-yl}oxy)methyl]-13-isopropyl-5-methyltetracyclo[7.4.0.0²,¹¹.0⁴,⁸]tridec-12-ene-1-carboxylic acid

C34H48O9 (600.3298)


   

(1r,2s,4r,5r,8r,9s,11s)-9-formyl-2-({[(2r,3s,4s,5r,6r)-3-hydroxy-5-methoxy-6-methyl-4-{[(2z,4z)-2-methylhexa-2,4-dienoyl]oxy}oxan-2-yl]oxy}methyl)-13-isopropyl-5-methyltetracyclo[7.4.0.0²,¹¹.0⁴,⁸]tridec-12-ene-1-carboxylic acid

(1r,2s,4r,5r,8r,9s,11s)-9-formyl-2-({[(2r,3s,4s,5r,6r)-3-hydroxy-5-methoxy-6-methyl-4-{[(2z,4z)-2-methylhexa-2,4-dienoyl]oxy}oxan-2-yl]oxy}methyl)-13-isopropyl-5-methyltetracyclo[7.4.0.0²,¹¹.0⁴,⁸]tridec-12-ene-1-carboxylic acid

C34H48O9 (600.3298)


   

1,3-bis(acetyloxy)-9,10-dihydroxy-7,8-dimethyl-7-(3-methylpenta-2,4-dien-1-yl)-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-5-yl deca-2,4-dienoate

1,3-bis(acetyloxy)-9,10-dihydroxy-7,8-dimethyl-7-(3-methylpenta-2,4-dien-1-yl)-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-5-yl deca-2,4-dienoate

C34H48O9 (600.3298)


   

{11-ethyl-9-hydroxy-4,6,8,16,18-pentamethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl}methyl 2-aminobenzoate

{11-ethyl-9-hydroxy-4,6,8,16,18-pentamethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl}methyl 2-aminobenzoate

C33H48N2O8 (600.341)


   

(1s,13s,14s,15r)-6,7-dihydroxy-14-methyl-1,13,15-tris(3-methylbut-2-en-1-yl)-14-(4-methylpent-3-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione

(1s,13s,14s,15r)-6,7-dihydroxy-14-methyl-1,13,15-tris(3-methylbut-2-en-1-yl)-14-(4-methylpent-3-en-1-yl)-3-oxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2(11),4,6,8-tetraene-10,12,17-trione

C38H48O6 (600.3451)


   

garcinialiptone b

garcinialiptone b

C38H48O6 (600.3451)


   

(1s,2r,6r,8r,10r,11s,12s,15r,16r,17s)-17-(acetyloxy)-2,16-dimethyl-5-oxo-15-[(1s)-1-[(3r,5r)-1,5,6,6-tetramethyl-2,7,8-trioxabicyclo[3.2.1]octan-3-yl]ethyl]-7-oxapentacyclo[9.7.0.0²,⁸.0⁶,⁸.0¹²,¹⁶]octadec-3-en-10-yl acetate

(1s,2r,6r,8r,10r,11s,12s,15r,16r,17s)-17-(acetyloxy)-2,16-dimethyl-5-oxo-15-[(1s)-1-[(3r,5r)-1,5,6,6-tetramethyl-2,7,8-trioxabicyclo[3.2.1]octan-3-yl]ethyl]-7-oxapentacyclo[9.7.0.0²,⁸.0⁶,⁸.0¹²,¹⁶]octadec-3-en-10-yl acetate

C34H48O9 (600.3298)


   

(2r,3s,4s,5r,6r)-3,4-dimethoxy-2-(methoxymethyl)-6-{[(2s,3s,4s)-1,3,4,5-tetramethoxypentan-2-yl]oxy}-5-{[(2r,3s,4r,5r,6s)-3,4,5-trimethoxy-6-methyloxan-2-yl]oxy}oxane

(2r,3s,4s,5r,6r)-3,4-dimethoxy-2-(methoxymethyl)-6-{[(2s,3s,4s)-1,3,4,5-tetramethoxypentan-2-yl]oxy}-5-{[(2r,3s,4r,5r,6s)-3,4,5-trimethoxy-6-methyloxan-2-yl]oxy}oxane

C27H52O14 (600.3357)


   

2-{3a,5a,7,8-tetrahydroxy-9a,11a-dimethyl-5-oxo-1h,2h,3h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-2,6-dihydroxy-6-methylheptan-3-yl benzoate

2-{3a,5a,7,8-tetrahydroxy-9a,11a-dimethyl-5-oxo-1h,2h,3h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-2,6-dihydroxy-6-methylheptan-3-yl benzoate

C34H48O9 (600.3298)


   

(1r,2r,3s,8r,10r,11r,15s,16s)-3-(acetyloxy)-15-[(3s)-5-(3,3-dimethyloxiran-2-yl)-2-oxooxolan-3-yl]-2,7,7,11,16-pentamethyl-5-oxo-6-oxatetracyclo[9.7.0.0²,⁸.0¹²,¹⁶]octadec-12-en-10-yl acetate

(1r,2r,3s,8r,10r,11r,15s,16s)-3-(acetyloxy)-15-[(3s)-5-(3,3-dimethyloxiran-2-yl)-2-oxooxolan-3-yl]-2,7,7,11,16-pentamethyl-5-oxo-6-oxatetracyclo[9.7.0.0²,⁸.0¹²,¹⁶]octadec-12-en-10-yl acetate

C34H48O9 (600.3298)